0001645113-19-000004.txt : 20191113 0001645113-19-000004.hdr.sgml : 20191113 20191113163014 ACCESSION NUMBER: 0001645113-19-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20191111 FILED AS OF DATE: 20191113 DATE AS OF CHANGE: 20191113 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GROENHUYSEN WILHELMUS CM CENTRAL INDEX KEY: 0001264783 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 191214387 MAIL ADDRESS: STREET 1: C/O NAVTEQ CORPORATION STREET 2: 222 MERCHANDISE MART STE 900 CITY: CHICAGO STATE: IL ZIP: 60654 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 4 1 wf-form4_157368059943557.xml FORM 4 X0306 4 2019-11-11 0 0001645113 NovoCure Ltd NVCR 0001264783 GROENHUYSEN WILHELMUS CM C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 0 1 0 0 Chief Financial Officer Ordinary Shares 2019-11-11 4 M 0 1900 3.44 A 89079 D Ordinary Shares 2019-11-11 4 S 0 1900 80.145 D 87179 D Ordinary Shares 2019-11-11 4 M 0 4800 3.44 A 91979 D Ordinary Shares 2019-11-11 4 S 0 4800 80.119 D 87179 D Ordinary Shares 2019-11-11 4 M 0 1900 7.03 A 89079 D Ordinary Shares 2019-11-11 4 S 0 1900 80.141 D 87179 D Ordinary Shares 2019-11-12 4 M 0 10000 3.44 A 97179 D Ordinary Shares 2019-11-12 4 S 0 10000 80.302 D 87179 D Ordinary Shares 2019-11-12 4 M 0 20000 3.44 A 107179 D Ordinary Shares 2019-11-12 4 S 0 20000 80.187 D 87179 D Ordinary Shares 2019-11-12 4 M 0 10000 7.03 A 97179 D Ordinary Shares 2019-11-12 4 S 0 10000 80.005 D 87179 D Options to Buy Ordinary Shares 3.44 2019-11-11 4 M 0 1900 0 D 2021-12-13 Ordinary Shares 1900.0 25169 D Options to Buy Ordinary Shares 3.44 2019-11-11 4 M 0 4800 0 D 2021-12-13 Ordinary Shares 4800.0 85832 D Options to Buy Ordinary Shares 7.03 2019-11-11 4 M 0 1900 0 D 2023-02-19 Ordinary Shares 1900.0 56386 D Options to Buy Ordinary Shares 3.44 2019-11-12 4 M 0 10000 0 D 2021-12-13 Ordinary Shares 10000.0 15169 D Options to Buy Ordinary Shares 3.44 2019-11-12 4 M 0 20000 0 D 2021-12-13 Ordinary Shares 20000.0 65832 D Options to Buy Ordinary Shares 7.03 2019-11-12 4 M 0 10000 0 D 2023-02-19 Ordinary Shares 10000.0 46386 D On November 11, 2019, Mr. Groenhuysen sold 1,900 shares in multiple trades at prices ranging from $80.00 to $80.38. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. On November 11, 2019, Mr. Groenhuysen sold 4,800 shares in multiple trades at prices ranging from $80.00 to $80.27. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. On November 12, 2019, Mr. Groenhuysen sold 10,000 shares in multiple trades at prices ranging from $80.00 to $80.85. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. On November 12, 2019, Mr. Groenhuysen sold 20,000 shares in multiple trades at prices ranging from $80.00 to $80.22. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. On November 12, 2019, Mr. Groenhuysen sold 10,000 shares in multiple trades at prices ranging from $80.00 to $80.09. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Options exercised were fully vested as of the date hereof. By: /s/ Todd Longsworth, Attorney in Fact for Wilhelmus CM Groenhuysen 2019-11-13 EX-24 2 ex-24.htm POWER OF ATTORNEY - GROENHUYSEN
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING PURPOSES

        Know all by these presents, that the undersigned hereby makes, constitutes and appoints Todd Longsworth, Kimberly Burke and Carrie Kane, acting individually, as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

        (1)    execute for, and on behalf of, the undersigned, in the undersigned's capacity as an officer, director and/or 10% beneficial owner of Novocure Limited (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder (the "Exchange Act");

        (2)    seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to any attorneys-in-fact and further approves and ratifies any such release of information;

        (3)    do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare, complete and execute any such Form 3, 4 or 5, and any amendments thereto, or other required report and timely file such Forms or reports with the United States Securities and Exchange Commission, the New York Stock Exchange and any stock exchange or similar authority as considered necessary or advisable under Section 16(a) of the Exchange Act; and

        (4)    take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in such attorney-in-fact's sole discretion.

        The undersigned hereby gives and grants to each such attorneys-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

        The undersigned hereby acknowledges that (a) the foregoing attorneys-in-fact are serving in such capacity at the request of the undersigned; (b) this Limited Power of Attorney authorizes, but does not require, each such attorneys-in-fact to act in his or her discretion on information provided to such attorneys-in-fact without independent verification of such information; (c) any documents prepared and/or executed by any attorneys-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorneys-in-fact, in his or her sole discretion, deems necessary or advisable; (d) neither the Company nor any attorneys-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act,
(ii) any liability of the undersigned for any failure to comply with such requirements or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and (e) this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including, without limitation, the reporting requirements under Section 16 of the Exchange Act.

        This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked as to any attorneys-in-fact by the undersigned in a signed writing delivered to such attorneys-in-fact.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of September, 2016.



        ___By: /s/ Wilco Groenhuysen___
            Signature


        ___Wilco Groenhuysen_________
            Print Name